| Model Number |
2800 |
| Medical Device Problem Codes |
Calcified (1077); Insufficient Device Problem Information (3190)
|
| Health Effect - Clinical Codes |
Dyspnea (1816); Insufficient Information (4580)
|
| Date of Event |
09/10/2025
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
H11: additional manufacturer narrative: the investigation is still in progress; therefore, a conclusion has yet to be established.A supplemental report will be submitted accordingly upon investigation completion.Edwards will continue to review and monitor all reported events.Trends are monitored on a monthly basis and if action is required, appropriate investigation will be performed.
|
| |
|
Event or Problem Description
|
|
It was learned through implant patient registry that a patient with a 25mm 2800 aortic valve was explanted after an implant duration of 9 years, 5 months due to unknown reasons.The explanted valve was replaced with a 25mm 11500a inspiris resilia aortic valve edwards lifesciences maintains an implant patient registry.This registry is a patient tracking mechanism for serialized edwards implantable devices (bioprosthetic heart valves and annuloplasty rings), rather than a true post-market surveillance registry.Through the registry, edwards is notified when these devices are implanted.In addition, patient and/or device status may be reported to the registry via the implantation data cards.The information is received from various sources (e.G.Surgeon, hospital, and patient family members) and is not received in the form of a conventional 'customer complaint'.The information reported may or may not be related to the edwards device.
|
| |
|
Event or Problem Description
|
|
It was learned through implant patient registry that a patient with a 25mm 2800 aortic valve was explanted after an implant duration of 9 years, 5 months due to calcification.The patient presented with dyspnea and fatigue.The explanted valve was replaced with a 25mm 11500a inspiris resilia aortic valve.Per medical records, patient had moderate aortic stenosis with severe mitral regurgitation.Patient underwent double valve replacement.Intraoperatively, aortic valve noted to have diseased, heavily calcified, and complete immobility of left leaflet and restriction of remaining 2 leaflets.Intraoperative tee demonstrated normal lv function with normal functioning of both newly implanted aortic and mitral bioprostheses.Patient was transported to cicu in stable condition and discharged on pod#9.Per pathology, aortic valve consisted of degenerative changes with calcification.Edwards lifesciences maintains an implant patient registry.This registry is a patient tracking mechanism for serialized edwards implantable devices (bioprosthetic heart valves and annuloplasty rings), rather than a true post-market surveillance registry.Through the registry, edwards is notified when these devices are implanted.In addition, patient and/or device status may be reported to the registry via the implantation data cards.The information is received from various sources (e.G.Surgeon, hospital, and patient family members) and is not received in the form of a conventional 'customer complaint'.The information reported may or may not be related to the edwards device.
|
| |
|
Additional Manufacturer Narrative
|
|
H11: additional manufacturer narrative: updated sections : b7, g3, g6, h2,h6 ( type of investigation).Corrected sections : b5, h6 ( component code , clinical code, device code, investigation findings and investigation conclusions).Svd is a logical and expected consequence of the chemical, mechanical, and immunological processes associated with bhv implantation.The common endpoint of all these factors is calcification and degradation.Svd is an acquired condition, intrinsic to bioprosthetic valves, characterized by deterioration of the leaflets or supporting structures, leading to thickening, calcification, tearing, or disruption of the prosthetic valve materials.These changes result in valvular dysfunction manifesting as stenosis and/or regurgitation with a consequent drop in hemodynamic efficacy of the valve.Despite the advancements in the heart valve industry, svd commonly begins 7- 8 years after implantation, with a considerably increased rate in patients with pertinent comorbidities and/or an implant duration of greater than 10 years.Prior investigations and extensive literature review have shown that svd is predominantly related to patient factors and implant duration rather than to manufacturing issues.Events related to device design, manufacturing, or use error tend to manifest at an earlier implant duration.There is no evidence to suggest a manufacturing defect caused or contributed to the reported event.Based on the information available, the most likely root cause is patient factors, including an implant duration of 7 or more years.A device history record (dhr) review is not performed because there is no allegation of a malfunction which could be related to a manufacturing non-conformance and/or one was not suspected or confirmed through investigation; no labeling non-conformance/deficiency; no device-related infection; and no evidence of a product failure with regard to design, reliability, or use error.
|
| |
|
Search Alerts/Recalls
|
|